- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly
Enrollment change, Trial completion date, Trial withdrawal, Combination therapy, Metastases: IBI397 or Combination Therapies in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 5, 2023 P1a/1b, N=0, Withdrawn, N=30 --> 0 | Trial completion date: Dec 2023 --> Aug 2023 | Recruiting --> Withdrawn
- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly
Enrollment open, Combination therapy, Metastases: IBI397 or Combination Therapies in Patients With Advanced Malignancies (clinicaltrials.gov) - Sep 19, 2022 P1a/1b, N=30, Recruiting, This dual and specific mechanism of AL008, to our knowledge, provides a novel therapeutic strategy for targeting myeloid cells for immune activation. Not yet recruiting --> Recruiting
|